You are currently viewing PVpharm starts a new collaboration with the International AIDS Vaccine Initiative (IAVI)

PVpharm starts a new collaboration with the International AIDS Vaccine Initiative (IAVI)

  • Post published:May 22, 2023

We are so excited to announce the new collaboration agreement signed by our company with the International AIDS Vaccine Initiative (IAVI) to provide pharmacovigilance and regulatory consulting. IAVI is a nonprofit scientific research organization that develops vaccines and antibodies for HIVtuberculosisemerging infectious diseases (including COVID-19), and other neglected diseases, with a clear commitment to develop affordable and accesible solutions to these diseases.

In the same way as our collaboration with the Leiden University Medical Center (LUMC) or with the Center for Human Drug Research (CHDR), PVpharm works to provide pharmacovigilance support in pre-approval phases of the development of innovative drugs. In this agreement, we also work in a very important fight for global public health: the creation of a effective vaccine against AIDS. This development got the support of different organizations, as the Danish Government, and it is a important hope to eradicate this disease with affordable and global solutions.

PVpharm provides services in all the phases of the medicinal product life cycle, and we have different services for sponsors of clinical trials in the EU. For more information, please read more at https://pvpharm.com/pharmacovigilance/

Please contact us with any question https://pvpharm.com/contact/